ArticleScientific reports2022
Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds.
Chiara Pallara et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it